Table 4.
10 irAEs unique for PD-L1/PD-1 inhibitors and 10 irAEs unique for CTLA-4 inhibitor
| Unique for PD-L1/PD-1 inhibitors | Unique for CTLA-4 inhibitor |
|---|---|
| (Total = 20) | (Total = 28) |
| Acute kidney injury | Acute respiratory distress syndrome |
| Dermatitis acneiform | Adrenocortical insufficiency acute |
| Embryo-fetal toxicity | Angiopathy |
| Hyperglycemia | Blepharitis |
| Hyponatremia | Cushing’s syndrome |
| Lymphopenia | Endocrine ophthalmopathy |
| Rash maculopapular | Hypogonadism |
| Rash pruritic | Mental status changes |
| Type 1 diabetes mellitus | Neurosensory hypoacusis |
| Urinary tract infection | Pericarditis |